A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

NCT07716098 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

348

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Treatment-Resistant

Interventions

DRUG: Esketamine 56 mg
DRUG: Esketamine 84 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC